

Drug Monograph

Drug/Drug **Aristada[®] (aripiprazole lauroxil) extended release**
Class: **suspension for injection/ Atypical Antipsychotics**
Prepared for: MO HealthNet
Prepared by: Conduent-Heritage

New Criteria

Revision of Existing Criteria

Executive Summary

Purpose: The purpose of this monograph is to provide a review of new therapy to determine whether the reviewed drug should be made available on an open access basis to prescribers, require a clinical edit or require prior authorization for use.

Dosage Forms: Aristada[®] is now available in a single-use prefilled syringe containing 1064 mg aripiprazole lauroxil per 3.9 ml.

Manufacturer: Alkermes, Inc., Waltham, MA 02451

Indications: Aristada[®] is indicated for treatment of schizophrenia.

Costs: \$712.46 per syringe of Aristada[®]. Maximum Allowable Cost

Summary of Findings: The Division recommends adding this drug to the current Atypical Antipsychotics clinical edit.

Status Recommendation: Prior Authorization (PA) Required Open Access
 Fiscal Edit Clinical Edit

Type of PA Criteria: Increased Risk of ADE Under Solicitation
 Appropriate Indications Non Preferred

Prepared By: Luke Boehmer Pharm.D.
Date: August 17, 2017